

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
19 June 2025 (19.06.2025)



(10) International Publication Number  
**WO 2025/128589 A9**



(51) International Patent Classification:

*C12N 15/113* (2010.01) *A61K 31/713* (2006.01)  
*C12N 15/85* (2006.01) *A61K 47/68* (2017.01)  
*A61K 31/712* (2006.01) *A61P 29/00* (2006.01)  
*A61K 31/7125* (2006.01)

(21) International Application Number:

PCT/US2024/059406

(22) International Filing Date:

10 December 2024 (10.12.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/609,643 13 December 2023 (13.12.2023) US

(71) Applicants: **ELI LILLY AND COMPANY** [US/US]; Lilly Corporate Center, Indianapolis, Indiana 46285 (US). **AVIDITY BIOSCIENCES, INC.** [US/US]; 10578 Science Center Dr., Suite 125, San Diego, California 92121 (US).

(72) Inventors: **BOYLES, Jeffrey**; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, 46206-6288 (UA). **BHATTACHARYA, Arvind**; c/o Avidity Biosciences, Inc., 10578 Science Center Dr., Suite 125, San Diego, California 92121 (US). **BROWN-AUGSBURGER, Patricia**; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **COCHRAN, Michael Caramian**; c/o Avidity Biosciences, Inc., 10578 Science Center Dr., Suite 125, San Diego, California 92121 (US). **DAVIES, Julian**; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **HOBBS, Wendy Loza**; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **KWAN, Yu Yan**; c/o Avidity Biosciences, Inc., 10578 Science Center Dr., Suite 125, San Diego, California 92121 (US). **MATALONGA BORREL, Jonatan**; c/o Avidity Biosciences, Inc., 10578 Science Cen-

ter Dr., Suite 125, San Diego, California 92121 (US). **MC-DERMOTT, Jeff S.**; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **OLIVA DETANICO, Thiago**; c/o Avidity Biosciences, Inc., 10578 Science Center Dr., Suite 125, San Diego, California 92121 (US). **WALL, Christopher Earle**; c/o Avidity Biosciences, Inc., 10578 Science Center Dr., Suite 125, San Diego, California 92121 (US).

(74) Agent: **SHANKAR, Neelaabh** et al.; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: COMPOSITIONS AND METHODS FOR MODULATING NAV1.8




FIG. 1A

(57) Abstract: The present disclosure is related to oligonucleotides, antibody-siRNA conjugates, or pharmaceutical compositions thereof for inhibiting the expression of Nav1.8 gene and methods of using such oligonucleotides, antibody-siRNA conjugates, or pharmaceutical compositions thereof in reducing/treating pain or diseases/disorders related to Nav1.8.

[Continued on next page]

**Declarations under Rule 4.17:**

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

**Published:**

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*

**(48) Date of publication of this corrected version:**

31 July 2025 (31.07.2025)

**(15) Information about Correction:**

see Notice of 31 July 2025 (31.07.2025)